1. Signaling Pathways
  2. Apoptosis
    Metabolic Enzyme/Protease
  3. Glutathione Peroxidase

Glutathione Peroxidase

Glutathione peroxidases (GPx) are a family of enzymes with the ability to reduce organic and inorganic hydroperoxides to the corresponding alcohols using glutathione or thioredoxin as an electron donor. These enzymes promote hydrogen peroxide metabolism and protect cell membrane structure and function from oxidative damage. Dysregulated GPx expression is connected with severe pathologies, including obesity and diabetes. GPx1 has been reported to be involved in both pro- and anticancer effects in different tumor models.

In mammals, the GPxs family consists of eight members (GPx1-GPx8) identified so far; five of them (GPx1-GPx4 and GPx6) contain selenocysteine in the catalytic center and the other three are cysteine-containing proteins. GPx1 is one of the most critical members of the GPxs family that catalytically reduces hydrogen peroxide to produce water. The function of GPx3 is to scavenge H2O2 and lipoperoxides in the plasma to reduce systematic oxidative stress and to maintain the bioavailability of vascular nitric oxide. Gpx4 is an essential mammalian glutathione peroxidase, which protects cells against detrimental lipid peroxidation and governs a novel form of regulated necrotic cell death, called ferroptosis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100218A
    RSL3
    Inhibitor 99.90%
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
    RSL3
  • HY-100003
    ML-210
    Inhibitor 99.89%
    ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
    ML-210
  • HY-100002
    ML162
    Inhibitor 99.52%
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
    ML162
  • HY-138153
    JKE-1674
    Inhibitor 98.30%
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors.
    JKE-1674
  • HY-B0182
    Carmofur
    Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
    Carmofur
  • HY-155663
    GPX4-IN-5
    Inhibitor 99.35%
    GPX4-IN-5 (Compound C18) is a GPX4 covalent inhibitor with an IC50 value of 0.12 μM. GPX4-IN-5 (Compound C18) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
    GPX4-IN-5
  • HY-155664
    GPX4-IN-6
    Inhibitor
    GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
    GPX4-IN-6
  • HY-163332
    MPO-IN-6
    Inhibitor
    MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent.
    MPO-IN-6
  • HY-141809
    GPX4-IN-3
    Inhibitor 99.90%
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.
    GPX4-IN-3
  • HY-135318
    NBDHEX
    Inhibitor 99.53%
    NBDHEX is a potent glutathione S-transferase P1-1 (GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor.
    NBDHEX
  • HY-N0070
    Solasonine
    Inhibitor 99.19%
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research.
    Solasonine
  • HY-111341
    AZD5904
    Inhibitor 99.93%
    AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
    AZD5904
  • HY-115627
    PKUMDL-LC-101-D04
    Activator 99.43%
    PKUMDL-LC-101-D04 (GPX4-Activator-1d4) is a potent ferroptosis regulator glutathione peroxidase 4 (GPX4) allosteric activator (pEC50=4.7). PKUMDL-LC-101-D04 increases GPX4 activity to 150% at 20 μM in the cell-free assay and 61 μM in cell extracts.
    PKUMDL-LC-101-D04
  • HY-17646
    Verdiperstat
    Inhibitor 99.60%
    Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
    Verdiperstat
  • HY-100873
    PF-1355
    Inhibitor 99.86%
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
    PF-1355
  • HY-115486
    MPO-IN-28
    Inhibitor 99.28%
    MPO-IN-28 (Compound 28) is a myeloperoxidase (MPO) inhibitor with an IC50 of 44 nM.
    MPO-IN-28
  • HY-B0880
    4-Aminobenzohydrazide
    Inhibitor 99.96%
    4-Aminobenzohydrazide is an irreversible MPO myeloperoxidase inhibitor with an IC50 of 0.3 µM. It is used for the research of subacute stroke.
    4-Aminobenzohydrazide
  • HY-N4288
    4-Methylesculetin
    Inhibitor 98.21%
    4-Methylesculetin is an orally active natural coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity and reduces IL-6 level.
    4-Methylesculetin
  • HY-145581
    Mitiperstat
    98.07%
    Mitiperstat (AZD4831) is the potent inhibitor of myeloperoxidase (MPO). Mitiperstat is particularly useful in the research of prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions (extracted from patent US20160152623A1).
    Mitiperstat
  • HY-120912
    Gingerenone A
    Activator
    Gingerenone A is a Nrf2-Gpx4 activator with anti-breast-cancer properties. Gingerenone A results a delayed G2/M in cancer cells, following oxidative stress and senescence responses. Gingerenone A also alleviates ferroptosis in secondary liver injury (SLI) in dextran sodium sulfate (DSS)-induced colitis mice. Gingerenone A can be isolated from Zingiber officinale.
    Gingerenone A
Cat. No. Product Name / Synonyms Application Reactivity